<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7525249\results\search\testTrace\results.xml">
  <result pre="more serious. First, there is a shortage of effective point-of-care" exact="testing" post="assays for rapid, highly accurate identification of SARS-CoV-2-infected individuals."/>
  <result pre="are highly contagious, and there is a lack of appropriate" exact="detection" post="assays. SARS-CoV emerged in 2002 and caused the disease"/>
  <result pre="genetic material) of severe acute respiratory syndrome coronavirus 2. Nucleotide" exact="detection" post="assay During the early period of the SARS-CoV-2 outbreak,"/>
  <result pre="of DNA-sequencing technology and the RT-PCR method [5]. Commercial nucleotide" exact="detection" post="methods Many molecular diagnostic companies and institutes are devoted"/>
  <result pre="developing integrated, random-access, point-of-care molecular devices for fast and accurate" exact="diagnosis" post="of SARS-CoV-2 infection [6]. As of 19 April 2020,"/>
  <result pre="point-of-care molecular devices for fast and accurate diagnosis of SARS-CoV-2" exact="infection" post="[6]. As of 19 April 2020, the US Food"/>
  <result pre="and Drug Administration had approved more than 37 SARS-CoV-2 RNA" exact="detection" post="kits (https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations). Non-commercialized RNA detection methods Many institutes are"/>
  <result pre="more than 37 SARS-CoV-2 RNA detection kits (https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations). Non-commercialized RNA" exact="detection" post="methods Many institutes are keen to adopt isothermal nucleic"/>
  <result pre="to adopt isothermal nucleic acid amplification technology for the point-of-care" exact="testing" post="of SARS-CoV-2, avoiding the need for a highly expensive"/>
  <result pre="targeting Nsp3 for SARS-CoV-2 detection, of which the limit of" exact="detection" post="was 100 copies per reaction [7]. Yu etÂ al."/>
  <result pre="ORF1ab and the spike gene, of which the limits of" exact="detection" post="were 20 copies/reaction and 200 copies/reaction, respectively, within 60"/>
  <result pre="coming months. WHO launched the Solidarity clinical trial for COVID-19" exact="treatment" post="to further evaluate remdesivir, hydroxychloroquine/chloroquine and lopinavir-ritonavir with and"/>
  <result pre="in China, with excellent efficacy and adequate safety in the" exact="treatment" post="of COVID-19-related pneumonia [37]. Chloroquine phosphate was also used"/>
  <result pre="is postulated that chloroquine could be used as a possible" exact="treatment" post="for individuals with COVID-19-related pneumonia [40]. Hydroxychloroquine Hydroxychloroquine, an"/>
  <result pre="preferred over chloroquine for its low ocular toxicity [42]. Prolonged" exact="treatment" post="(at least 5 years) with hydroxychloroquine may cause retinopathy,"/>
  <result pre="remdesivir in seriously ill patients. Treatment at the time of" exact="diagnosis" post="is the key outcome for individuals with COVID-19; however,"/>
  <result pre="inhibitors that are usually used to treat human immunodeficiency virus" exact="infection" post="with and a booster drug ritonavir. Lopinavir and/or ritonavir"/>
  <result pre="reduced viral load were not significantly different among the lopinavir/ritonavir" exact="treatment" post="group (nÂ =Â 52), arbidol treatment group (nÂ =Â"/>
  <result pre="different among the lopinavir/ritonavir treatment group (nÂ =Â 52), arbidol" exact="treatment" post="group (nÂ =Â 34) and control group (nÂ =Â"/>
  <result pre="care (arbidol plus interferon-Î± inhaler) in five patients with combined" exact="treatment" post="of lopinavir/ritonavir plus the standard of care (arbidol plus"/>
  <result pre="trial of 199 individuals with severe COVID-19, compared with standard" exact="treatment" post="alone, lopinavir/ritonavir (400/100 mg) was added to standard treatment"/>
  <result pre="standard treatment alone, lopinavir/ritonavir (400/100 mg) was added to standard" exact="treatment" post="twice a day for 14 consecutive days and did"/>
  <result pre="receiving lopinavir/ritonavir. The proportion of early discontinuation for with lopinavir/ritonavir" exact="treatment" post="was 14%. The patients engaged in this study had"/>
  <result pre="14%. The patients engaged in this study had a progressive" exact="infection" post="and previously had considerable tissue damage (as shown by"/>
  <result pre="detected in an ad hoc subgroup of patients who received" exact="treatment" post="within 12 days of symptom onset, but not in"/>
  <result pre="days of symptom onset, but not in patients who received" exact="treatment" post="later [63]. In another study of 280 individuals with"/>
  <result pre="280 individuals with COVID-19, the time from onset to antiviral" exact="treatment" post="was considered a risk factor for serious illness. Patients"/>
  <result pre="for serious illness. Patients in the mild group received antiviral" exact="treatment" post="earlier (Severe group 1.19Â Â±Â 0.45 days compared with"/>
  <result pre="with 2.65Â Â±Â 1.06 days, pÂ 62]. Whether early COVID-19" exact="treatment" post="with lopinavir/ritonavir has clinical applications is an important question"/>
  <result pre="and the type I IFN pathway. Nitazoxanide interferes with viral" exact="infection" post="by up-regulating the specific host mechanism of viral targeting"/>
  <result pre="and viral proteins. It has been shown to limit the" exact="infection" post="of certain RNA viruses (including influenza virus, dengue fever"/>
  <result pre="A single addition to Vero-hSLAM cells 2 hours after their" exact="infection" post="with SARS-CoV-2 can effectively reduce the viral RNA approximately"/>
  <result pre="two were withdrawn from the ventilator after 5 days of" exact="treatment" post="[72]. Low number of lymphocytes is an important sign"/>
  <result pre="number of lymphocytes is an important sign of severity and" exact="diagnosis" post="in COVID-19 patients [73]. In a study with tocilizumab,"/>
  <result pre="with two critical individuals. Hence, tocilizumab can be an efficient" exact="treatment" post="for severe COVID-19, which may be due to the"/>
  <result pre="part of the random evaluation of the Oxford University's COVID-19" exact="treatment" post="(RECOVERY) trial, some patients are being treated with steroids."/>
  <result pre="when the drug should be used in COVID-19 [74]. COVID-19" exact="detection" post="methods Worldwide research approaches have been adopted to respond"/>
  <result pre="to respond to the rapidly growing COVID-19 pandemic based on" exact="testing" post="capabilities, public health resources and the spread of viruses"/>
  <result pre="and the spread of viruses among populations. Molecular based laboratory" exact="testing" post="Currently, the US CDC recommended strategy for identifying individuals"/>
  <result pre="are subjected to RNA extraction, followed by target-specific nucleic acid" exact="detection" post="through qualitative RT-PCR. The CDC and WHO have developed"/>
  <result pre="CDC and WHO have developed the most widely used SARS-CoV-2" exact="detection" post="method. The kit designed by CDC contains PCR primer"/>
  <result pre="envelope (E) gene and RNA-dependent RNA polymerase (RdRP) [77]. Both" exact="detection" post="methods have high detection sensitivity and specificity for SARS-CoV-2"/>
  <result pre="RNA-dependent RNA polymerase (RdRP) [77]. Both detection methods have high" exact="detection" post="sensitivity and specificity for SARS-CoV-2 and have limited cross-reactivity"/>
  <result pre="20 days after the onset of symptoms using PCR; however," exact="isolation" post="of the virus is not possible after day 8"/>
  <result pre="been suggested that the sensitivity of amplification on gene E" exact="detection" post="would be less than on gene N. Moreover, the"/>
  <result pre="tests Diagnosis approaches that identify antigens for respiratory syncytial virus" exact="infection" post="or influenza virus infection directly from clinical samples through"/>
  <result pre="identify antigens for respiratory syncytial virus infection or influenza virus" exact="infection" post="directly from clinical samples through immunoassays have been commercialized"/>
  <result pre="developed and may form the basis of future rapid antigen" exact="detection" post="tests [86]. Serology Serological tests, such as ELISA, can"/>
  <result pre="molecular tests and may be used in some cases for" exact="diagnosis" post="[87]. However, at the onset of symptoms, when the"/>
  <result pre="and transmission seems to be highest, their use in the" exact="diagnosis" post="of acute infections may be limited [78]. Antibody response"/>
  <result pre="acute infections may be limited [78]. Antibody response to viral" exact="infection" post="may take several days to be reliably detected [87]."/>
  <result pre="In patients with advanced disease complications during drug therapy, serological" exact="testing" post="may be more important, because RT-PCR may be false"/>
  <result pre="to develop serological tests that can accurately assess previous SARS-CoV-2" exact="infection" post="and immunity. In some countries/regions, immunoassays are already on"/>
  <result pre="suspected of having the virus may be useful for initial" exact="screening" post="[91]. However, early reports indicate that preliminary imaging examinations"/>
  <result pre="to all procedures and techniques to reduce the risk of" exact="infection" post="by medical staff and patients [73]. Vaccines updates SARS-CoV-2"/>
  <result pre="of volunteers have been injected with preparations; others have begun" exact="testing" post="in animals (https://www.nature.com/articles/d41586-020-01221-y).Research teams from different universities and companies"/>
  <result pre="vaccine (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines). TableÂ 1 Profile of antivirals investigated for COVID-19" exact="treatment" post="in clinical trials or inÂ vitro studies. Source: WHO,"/>
  <result pre="development and application of new tools. At the forefront, the" exact="diagnosis" post="of SARS-COV-2 from clinical samples must be rapid and"/>
  <result pre="such as molecular based tests, serology, radiography and antigen base" exact="detection" post="and vaccines. Some of the drugs are not effective"/>
  <result pre="that could potentially targetÂ all coronaviruses may be the only" exact="treatment" post="option to prevent re-emerging and circulating coronaviruses. Moreover, new"/>
  <result pre="and circulating coronaviruses. Moreover, new data on the clinical characteristics," exact="treatment" post="options and outcomes of COVID-19 appear constantly, and doctors"/>
  <result pre="coronavirusesTrends Microbiol24201649050227012512 4IsaacsD.FlowersD.ClarkeJ.R.ValmanH.B.MacNaughtonM.R.Epidemiology of coronavirus respiratory infectionsArch Dis Child5819835005036307189 5YuF.YanL.WangN.YangS.WangL.TangY.Quantitative" exact="detection" post="and viral load analysis of SARS-CoV-2 in infected patientsClin"/>
  <result pre="patientsClin Infect Dis Off Publ Infect Dis Soc Am71152020793798 6LoeffelholzM.J.TangY.W.Laboratory" exact="diagnosis" post="of emerging human coronavirus infectionsâ€&quot;the state of the artEmerg"/>
  <result pre="Infect Dis742020ofaa10532284951 37GaoJ.TianZ.YangX.Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci Trends142020727332074550 38TortoriciM.A.WallsA.C.LangY.WangC.LiZ.KoerhuisD.Structural"/>
  <result pre="the big data and the real world2020100709 45AndreaniJ.Le BideauM.DuflotI.JardotP.RollandC.BoxbergerM.InÂ vitro" exact="testing" post="of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic"/>
  <result pre="patients treated with favipiravir (T-705)-Sierra Leone, 2014Clin Infect Dis6320161288129427553371 54CorrectionExperimental" exact="treatment" post="with favipiravir for Ebola virus disease (the JIKI trial):"/>
  <result pre="studyTravel Med Infect Dis34202010166332289548 59YeX.T.LuoY.L.XiaS.C.SunQ.F.DingJ.G.ZhouY.Clinical efficacy of lopinavir/ritonavir in the" exact="treatment" post="of Coronavirus disease 2019Eur Rev Med Pharmacol Sci2420203390339632271456 60ChenC.Y.WangF.L.LinC.C.Chronic"/>
  <result pre="the search for effective therapyNÂ Engl J Med38220201851185232187463 63ÅžimÅŸek YavuzS.ÃœnalS.Antiviral" exact="treatment" post="of COVID-19Turk J Med Sci50Si-1202061161932293834 64RossignolJ.F.Nitazoxanide, a new drug"/>
  <result pre="J Med Sci50Si-1202061161932293834 64RossignolJ.F.Nitazoxanide, a new drug candidate for the" exact="treatment" post="of Middle East respiratory syndrome coronavirusJÂ Infect Public Health9201622723027095301"/>
  <result pre="efficacy of ivermectin for prevention of a lethal Zika virus" exact="infection" post="in a murine systemDiagn Microbiol Infect Dis952019384031097261 68KalyL.RosnerI.Tocilizumabâ€&quot;a novel"/>
  <result pre="in severe pulmonary syndrome patients of a new coronavirus2020202002.12.945576 72XuX.HanM.LiT.SunW.WangD.FuB.Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc Natl Acad Sci"/>
  <result pre="infectious disease wardsEur J Clin Microbiol Infect Dis3920201059106132342252 81PrendergastC.PapenburgJ.Rapid antigen-based" exact="testing" post="for respiratory syncytial virus: moving diagnostics from bench to"/>
  <result pre="from bench to bedside?Future Microbiol8201343544423534357 82ChartrandC.TremblayN.RenaudC.PapenburgJ.Diagnostic accuracy of rapid antigen" exact="detection" post="tests for respiratory syncytial virus infection: systematic review and"/>
  <result pre="83MerckxJ.WaliR.SchillerI.CayaC.GoreG.C.ChartrandC.Diagnostic accuracy of novel and traditional rapid tests for influenza" exact="infection" post="compared with reverse transcriptase polymerase chain reaction: a systematic"/>
  <result pre="enzyme-linked immunosorbent assayJÂ Clin Microbiol4220042884288915243033 85ChenY.ChanK.H.KangY.ChenH.LukH.K.PoonR.W.AÂ sensitive and specific antigen" exact="detection" post="assay for Middle East respiratory syndrome coronavirusEmerg Microb Infect42015e26"/>
  <result pre="disease (COVID-19)Clin Infect Dis2020 88PatrickD.M.PetricM.SkowronskiD.M.GuaspariniR.BoothT.F.KrajdenM.An outbreak of human coronavirus OC43" exact="infection" post="and serological cross-reactivity with SARS coronavirusCan J Infect Dis"/>
  <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort studyLancet Infect Dis20202056557432213337 90HosseinyM.KoorakiS.GholamrezanezhadA.ReddyS.MyersL.Radiology"/>
 </snippets>
</snippetsTree>
